Please ensure Javascript is enabled for purposes of website accessibility

Why VYNE Therapeutics Stock Is Crashing Today

By Keith Speights - May 6, 2021 at 11:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker reported disappointing Q1 results.

What happened

Shares of VYNE Therapeutics (VYNE -3.04%) were crashing 18.1% lower as of 11:35 a.m. EDT on Thursday. The big decline came after the company announced its first-quarter results before the market opened.

So what

VYNE reported Q1 revenue of $4.1 million, up from $1.8 million in the prior-year period. Despite the significant year-over-year increase, this result fell well below the average analyst revenue estimate of $5.3 million.

Man wearing a coat and tie holding a red line with an arrow trending down

Image source: Getty Images.

The company's revenue growth stemmed from higher sales for topical skin medication Amzeeq and Zilxi. VYNE launched Zilxi in October 2020 after receiving approval earlier that year by the U.S. Food and Drug Administration (FDA) for the drug in treating rosacea.

Lower-than-expected sales haven't been the only challenge for the biotech stock. VYNE executed a 1-for-4 reverse stock split in the first quarter to boost its share price and reduce its number of outstanding shares.

Now what

VYNE Therapeutics hopes to have better news on the way later this year. The company plans to advance FMX114 into a phase 2a study in the third quarter for treating mild-to-moderate atopic dermatitis. Top-line results from this study are expected before the end of 2021.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Foamix Pharmaceuticals Ltd. Stock Quote
Foamix Pharmaceuticals Ltd.
VYNE
$0.33 (-3.04%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.